Short-term chemotherapy of poor-prognosis metastatic XXXX with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study.

@entity1 @entity632 @entity137 @entity0 @entity1138 @entity786 @entity1891 @entity5713 @entity3 @entity1487
A Southwest Oncology Group pilot study was designed to evaluate a brief, 4.5-month induction course of chemotherapy with three presumably non-cross resistant regimens in poor-prognosis metastatic @entity0 . Sixty-three @entity1 were treated with @entity632 , @entity786 , plus @entity1891 on day 1, methotrexate followed 30 minutes later by @entity1487 ( @entity1487 ) on day 22, and @entity1138 plus 3 days of @entity5713 on day 43. All three sequential regimens were repeated once and therapy was then discontinued in responding @entity1 . The same chemotherapy was reinstituted at the time of relapse. The overall response rate to the induction chemotherapy was 35% and included only one complete response (2%). Median response duration was 9 months. Respondents were off all therapy for a median of 5 months (range, 1-12+ months) and were followed without evidence of progressive disease. Response to retreatment was 30% with no complete responses seen. Overall median survival from the data of diagnosis of @entity3 was 24 months, with a median survival of 14 months from the date of initiation of therapy. @entity137 for this induction regimen was moderate with two treatment-related deaths secondary to myelosuppression. While the results of this pilot study fail to support the use of non-cross resistant regimens in @entity0 , short-term therapy appears to have no adverse effect on survival and resulted in significant periods during which no therapy was given, resulting in a reduction in overall @entity137 .
